Tackling Emerging Co-Infections

人类持续暴露于多种病原体，但除了少数明确界定的合并感染情况（例如艾滋病毒和结核病）外，对合并感染对发病率和死亡率的影响知之甚少。越来越多的证据表明，合并感染很常见，会加剧疾病的严重程度，并可能大大恶化结果（例如流感或COVID-19相关的曲霉菌感染）。与耐药病原体的合并感染已显示出增加了另一层复杂性，导致高病死率。我们的目标是整合和利用正在处理主要病原体组[病毒，细菌，真菌和寄生虫]的四个中心的专业知识，以促进联合王国范围内对合并感染疾病的病理生理影响和机制基础的研究。

Humans are continuously exposed to multiple pathogens yet, with the exception of a few well defined coinfection scenarios (HIV and tuberculosis for example), relatively little is known about the impact of co-infections on morbidity and mortality. There is growing evidence indicating that co-infections are common, exacerbate disease severity and can considerably worsen outcome (Influenza or COVID-19 associated Aspergillus infection for example). Co-infections with drug-resistant pathogens have shown to add another layer of complexity with high case-fatality rates. Our aim is to integrate and exploit the expertise of four Centres that are tackling the major pathogen groups [viruses, bacteria, fungi and parasites] to promote UK-wide research on the pathophysiological impact and mechanistic basis of disease in co-infections.